title: Re: Chia et al.: Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops (Ophthalmology 2016;123:391-9).
authors.affiliation: Ophthalmologist Supraspecialist in Cornea, Refractive Surgery and Anterior Segment, Fundación Oftalmológica de Santander FOSCAL, Floridablanca, Colombia.
authors.forename: Virgilio
authors.initials: V
authors.lastname: Galvis
authors.affiliation: Ophthalmologist Supraspecialist in Cornea, Refractive Surgery and Anterior Segment, Fundación Oftalmológica de Santander FOSCAL, Floridablanca, Colombia.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Tello
authors.affiliation: Ophthalmology Resident, Fundación Oftalmológica de Santander FOSCAL, Universidad Industrial de Santander UIS, Bucaramanga, Colombia. Electronic address: mariamargaritaparrac@gmail.com.
authors.forename: M Margarita
authors.initials: MM
authors.lastname: Parra
authors.affiliation: Optometrist, Centro Oftalmológico Virgilio Galvis, Floridablanca, Colombia.
authors.forename: Carlos J
authors.initials: CJ
authors.lastname: Rodriguez
authors.affiliation: Optometrist, Centro Oftalmológico Virgilio Galvis, Floridablanca, Colombia.
authors.forename: Oscar
authors.initials: O
authors.lastname: Blanco
mesh_terms: D001285:Atropine; D006801:Humans; D009184:Mydriatics; D009216:Myopia; D009883:Ophthalmic Solutions
chemical_list: D009184:Mydriatics; D009883:Ophthalmic Solutions; D001285:Atropine